Immune checkpoint inhibitors in cervical cancer: Current status and research progress.

Front Oncol · 2022 · PMC9647018 · PMID 36387196

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Data from the KEYNOTE-158 trial showed that the proportion of TMB-H cases for cervical cancer is approximately 15%, and TMB-H cervical cancer tumors showed a trend toward better response rates ( 36 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.